# EDGAR Filing Document

**Accession Number:** 0001641489
**File Stem:** 0001415889-25-023816
**Filing Date:** 2025-9
**Character Count:** 7852
**Document Hash:** 5550b82ef5587bb45c26b6fd6227ae47
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-023816.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001415889-25-023816

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250903

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AKKARAJU SRINIVAS
- **CENTRAL INDEX KEY:** 0001253170

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37524
- **FILM NUMBER:** 251297728

**MAIL ADDRESS:**
- **STREET 1:** 565 EVERETT AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** vTv Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001641489
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473916571
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3980 PREMIER DR
- **STREET 2:** SUITE 310
- **CITY:** HIGH POINT
- **STATE:** NC
- **ZIP:** 27265
- **BUSINESS PHONE:** 336-841-0300

**MAIL ADDRESS:**
- **STREET 1:** 3980 PREMIER DR
- **STREET 2:** SUITE 310
- **CITY:** HIGH POINT
- **STATE:** NC
- **ZIP:** 27265

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VTV Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150506

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AKKARAJU SRINIVAS<br><sub>(Last) (First) (Middle)</sub><br>C/O VTV THERAPEUTICS INC.<br>3980 PREMIER DRIVE, SUITE 310<br><sub>(Street)</sub><br>HIGH POINT, NC 27265<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>vTv Therapeutics Inc. [ VTVT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Pre-Funded Warrants (Right to Buy) | $0.01 | 2025-09-03 |  | A<sup>(1)</sup> |  | 655523 |  | <sup>(2)</sup> | <sup>(2)</sup> | Class A Common Stock | 655523 | <sup>(1)</sup> | 1548101 | I | Samsara BioCapital, L.P.<sup>(3)</sup> |
| Warrant to Purchase Class A Common Stock (Right to Buy) | $22.71 | 2025-09-03 |  | A<sup>(1)</sup> |  | 655523 |  | <sup>(4)</sup> | <sup>(4)</sup> | Class A Common Stock | 655523 | <sup>(1)</sup> | 655523 | I | By Samsara BioCapital, L.P.<sup>(3)</sup> |

---

### Footnotes:

(1) On August 29, 2025, Samsara BioCapital, L.P. ("Samsara LP") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock.

(2) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

(3) These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

(4) The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met.  A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

**Signature:** /s/ Srinivas Akkaraju  
**Date:** 2025-09-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**